Tregs can inhibit the anti-tumor cytotoxic activity of CD8+ T cells, NK cells and NKT cells, thereby leading to anti-tumor cell exhaustion, immune evasion and tumor progression [121]. This evidence concerns the gene CD8A and neoplasm.